Used in pharmaceutical research as a key intermediate for synthesizing targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, making it valuable in developing anticancer agents, especially for hematological malignancies like multiple myeloma. Also explored in the design of PROTACs (proteolysis-targeting chimeras) due to its ability to recruit E3 ubiquitin ligase, facilitating degradation of disease-causing proteins. Shows potential in improving drug specificity and overcoming resistance in oncology therapies.